Going Global Gets Stuck, Chinese Drug Makers CRL Show What Not To Do
Holistic not opportunistic approach required
Executive Summary
Chinese drug makers have more to lament and plenty to learn from as Junshi, HutchMed follow Innovent Bio with FDA rejections. A holistic not opportunistic approach is needed, one ex-FDA expert suggests.
You may also be interested in...
ESMO: Positive Results Buoy Chinese Oncology Developers' Global Hopes
Promising new clinical results presented at ESMO are likely to help several Chinese firms gain traction to take their new drug candidates into global markets, including the US.
Henlius Forges Ahead With US PD-1 Plans Despite Peers' Setbacks
The latest step by the Chinese drug maker to support its international ambitions is a bridging study in the US, which will evaluate its PD-1 contender serplulimab against Roche’s PD-L1-targeted Tecentriq.
US FDA’s Project Site Selector Kicks Off With A Look At Why Cancer Trials Go Overseas
Speed, logistics and global regulatory demands are all reasons why sponsors increasingly look outside the US to enroll cancer trials, industry reps say during the inaugural event for the Oncology Center of Excellence's new initiative; OCE director Pazdur says multiregional trials can help provide patients access to important new drugs quickly in the US or worldwide.